SEC Filings
Vertex Assigns $5.1 Billion Of Its Crinetics Price To One Unapproved Drug
Vertex's preliminary accounting puts $5,116.0 million on atumelnant, a Phase 3 drug, against $1,335.4 million of goodwill.
Vertex Pharmaceuticals (VRTX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Vertex's preliminary accounting puts $5,116.0 million on atumelnant, a Phase 3 drug, against $1,335.4 million of goodwill.
Earnings
Third-quarter sales rose 12% to $3.44 billion, while net income fell to $653.6 million on costs tied to the Crinetics purchase.
SEC Filings
Brennan, a CPA, also joins the Audit and Finance Committee and receives a $400,000 restricted stock unit award vesting in October 2027.